Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$1.25 USD
+0.02 (1.52%)
Updated Apr 22, 2024 11:50 AM ET
After-Market: $1.23 -0.02 (-1.58%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APTO 1.25 +0.02(1.52%)
Will APTO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APTO
What Makes Aptose Biosciences (APTO) a New Buy Stock
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
Other News for APTO
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Aptose Biosciences’ Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Aptose Reports Results for the Fourth Quarter and Full Year 2023